BioValley Basel will hold its yearly BioValley event with a round table discussion on the status if the Life Sciences innovation cluster Basel, role of the state, key ingredients for innovation, culture of failure and key factors of a successful ecosystem. Where are we falling behind, where do we need to pre-pare the key success factors? Have we learnt from mistakes and are we hungry enough and prepared for the future? How important is the cluster if you seek to collaborate with the best, regardless of location. In the first part we will focus on the status quo with score cards for different areas. In the second we will focus on the identified gaps.

Moderators: Sara Núñez-Garcia and Matthias Staehelin, Board BioValley

Panelists:

Simon Ittig

Simon Ittig is CEO of T3 Pharmaceuticals which was acquired by Boehringer Ingelheim in 2023. He completed a PhD on microbial pathogenesis at the University of Basel in the framework of the Werner Siemens Excellence fellowships. He started working on the T3 Pharma technology during his postdoctoral studies at the Biozentrum Basel. For these achievements he received the Novartis and University of Basel Excellence Scholarship, the research prize from the Huggenberger-Bischoff foundation and very recently the Cancer Prize of the Krebsliga Basel.

Karin Sartorius

Karin Sartorius is the Innovation Manager Life Sciences at Innovation Promotion, Office of Economy and Labor of the Canton of Basel-Stadt. In addition to her primary role, she serves as a Board Member of the DayOne Health 4.0 Accelerator and is the Chair of the Congress Board Basel. She is also the Initiator and Co-Founder of the association “POWHER - Female Entrepreneurs Basel”. Karin's extensive experience includes serving as a member of the Basel-Stadt parliament, where she was President of the Petitions Commission and a Member of the Health & Social Affairs Committee. Her professional background spans several positions within the bio- and medtech sectors, covering roles from research to commercialization.

Nigel Sheail

Nigel Sheail is a venture partner at Versant based in Basel, Switzerland. Prior to joining Versant, Nigel was Global Head of Mergers & Acquisitions and Business Development & Licensing at Novartis, where he served as a member of the company’s senior leadership team. In that role, he was responsible for the execution of a broad range of healthcare deals spanning research and technology collaborations through to large M&A transactions. Prior to Novartis, Nigel was Head of Business Development and Licensing for Bayer Healthcare, and before that served as Head of Group M&A at Roche and Head of Licensing for its Pharma division.

Christian Schneider

Since 2017, Christian is leading the Innovation Office at the University of Basel, which is the central contact point at the University for all matters related to innovation and entrepreneurship. As such, the office is operating a variety of thematic platforms and projects, offers entrepreneurial educations, enables public-private collaborations and supports start-ups and spin-offs on their journey to achieve impact. Previous work experience includes acting as Head of Science & Technology Office at the Embassy of Switzerland in Korea and Australia.

Marina Udier

Marina Udier currently serves as CEO of Nouscom, a private oncology company developing next-generation immunotherapies, after joining as Chief Operating Officer in 2016 from Versant Ventures. Prior to Versant, she held various senior development and commercial roles at Novartis Pharma in Basel. She spent five years with McKinsey & Company in Chicago, working with Healthcare Fortune 500 companies in areas of marketing, strategy and pricing. Marina Udier received her PhD in Organic Chemistry from Yale University.

Please register for the event via the following button by Thursday, 15 August 2024. Places are limited.